Your browser doesn't support javascript.
Meeting Fill/Finish Challenges for COVID-19 Vaccines
Pharmaceutical Technology Europe ; 33(3):42-43, 2021.
Article in English | ProQuest Central | ID: covidwho-20239801
ABSTRACT
"Lyophilization may be necessary to decrease prohibitive storage temperature requirements, allowing for shipment and storage in areas of the world where refrigeration isn't as easily accessed. "The challenge posed by the COVID-19 vaccines at the fill/finish stage of manufacturing stems from the fact that these candidates are dispersions," adds Eatmon, who explains that the dispersion factor makes the vaccines sensitive to shear stress because they are a lipid nanoparticle rather than a solution. [...]the manufacturer or CDMO/ CMO must pay close attention to foaming during liquid formulation filling and must reduce the rate of vial filling to accommodate excipients that foam, she notes. Other than the API, excipients sometimes include antibiotics, to prevent contamination by bacteria;adjuvants that help stimulate a stronger immune response;and stabilizers, to keep the vaccine potent during transportation and storage," he notes, further explaining that the types of API used all help to ensure the product's stability, and that each type plays a different role while in storage. cdmo/cmo readiness Fill/finish operations are predominantly outsourced to CDMOs/CMOs, which are well suited to handle COVID-19 vaccines as these products start to hit the market.
Keywords
Search on Google
Collection: Databases of international organizations Database: ProQuest Central Topics: Vaccines Language: English Journal: Pharmaceutical Technology Europe Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: ProQuest Central Topics: Vaccines Language: English Journal: Pharmaceutical Technology Europe Year: 2021 Document Type: Article